
Superpower peptides available for pre-order. Get first access.

Peptide science
What is maritide (MariTide)?
MariTide (maridebart cafraglutide, AMG 133) is an investigational monthly GIPR blocker and GLP-1 activator. See Phase 2 data and Phase 3 status.
Quick answer
MariTide (maridebart cafraglutide, AMG 133) is Amgen's investigational once-monthly antibody-peptide conjugate that blocks the GIP receptor and activates the GLP-1 receptor. In a 52-week Phase 2 trial of adults with obesity and no diabetes, average weight loss was 12.3% to 16.2% vs 2.5% on placebo. In an analysis assuming people stayed on treatment, weight loss had not plateaued by week 52. Phase 3 MARITIME trials are underway, and MariTide is not FDA-approved.
- Published
- April 18, 2026
- Last updated
- November 12, 2026
Key takeaways
- Regulatory status: As of November 2026, MariTide is not FDA-approved and is in Phase 3 clinical trials1.
- Research stage: The first Phase 1 trial2 and main Phase 2 trial are completed3, and Phase 3 MARITIME trials are ongoing.
- Availability: Access is limited to clinical trial enrollment, and Superpower does not offer MariTide.
- Prescribing information: The MARITIME-1 trial registration4 serves in place of a label.
- How it works: MariTide's antibody blocks the GIP receptor2, and its two attached peptides activate the GLP-1 receptor.
- What the research shows: In a 52-week Phase 2 trial in adults with obesity without diabetes, average weight loss was 12.3% to 16.2%5 vs 2.5% on placebo, counting everyone in each group, including people who stopped treatment.
What MariTide is and how it works
MariTide (maridebart cafraglutide, AMG 133) is an Amgen antibody-peptide conjugate: an antibody that blocks the receptor for glucose-dependent insulinotropic polypeptide (GIP), joined to two GLP-1 peptides2 that activate the GLP-1 receptor.
GIP and GLP-1 are gut hormones that help release insulin6 after meals. GLP-1 receptor agonists also slow stomach emptying and reduce food intake7.
MariTide's antibody backbone keeps the attached peptides in circulation8 far longer than free peptides. In monkeys, the GLP-1 peptide's half-life rose from minutes to over nine days9. In Phase 1, MariTide's half-life of about 21 days2 supported monthly dosing.
In mice and monkeys, GIP receptor-blocking antibodies limited weight gain or caused weight loss10, adding to the effect of GLP-1 drugs.
The conjugate design grew out of earlier antibody-peptide molecules that lowered weight in obese mice and monkeys11.
Why both blocking and activating the GIP receptor lower weight is still debated12. Mouse and cell studies suggest one explanation: constant activation desensitizes fat-cell GIP receptors13, mimicking a blocker.
Tirzepatide activates both the GIP and GLP-1 receptors14, while MariTide blocks the first and activates the second. The contrast is for scientific context only, since the two drugs differ in regulatory status and evidence base. Human trials tested what that pairing does in people.
What the MariTide Phase 1 and Phase 2 trials show
In a 52-week Phase 2 trial of 592 adults, MariTide lowered weight 12.3% to 16.2% in those without diabetes5, vs 2.5% with placebo. The table's figures come from the treatment-policy analysis, which counts everyone assigned to a group, including people who stopped treatment.
Phase 2 results at 52 weeks, 140 to 420 mg5 every four or eight weeks:
| Outcome and cohort | Participants | MariTide (range across doses) | Placebo |
| Weight change, obesity without type 2 diabetes | 465 | −12.3% to −16.2%5 | −2.5% |
| Weight change, obesity with type 2 diabetes | 127 | −8.4% to −12.3%5 | −1.7% |
| HbA1c change, obesity with type 2 diabetes | 127 | −1.2 to −1.6 percentage points5 | +0.1 percentage points |
Weight loss was smaller in adults with type 2 diabetes, whose HbA1c also fell. In an analysis assuming people stayed on treatment, average weight loss had not plateaued by week 5215.
MariTide's 110-person Phase 1 trial enrolled adults with obesity. On the top multiple-dose regimen of 420 mg every four weeks, weight fell about 14.5% by day 852, vs about 1.5% change with placebo. Weight loss in the multiple-dose groups held for as long as 150 days2 after the last dose. Phase 3 has not yet confirmed that 150-day result.
The Phase 3 MARITIME-SWITCH trial is testing injections every eight weeks or quarterly1 in adults switching from a weekly GLP-1 drug16. Approval depends on what the larger Phase 3 program shows.
MariTide FDA status and Phase 3 timeline
As of November 2026, MariTide is not FDA-approved and remains in the Phase 3 MARITIME program1. Phase 3 studies test effectiveness and monitor adverse reactions17 in hundreds to thousands of people. The main MARITIME trials differ by population:
- MARITIME-1: 3,853 adults with obesity or overweight4 and no type 2 diabetes, primary completion expected January 2027
- MARITIME-2: 1,105 adults with type 2 diabetes18 and obesity or overweight, primary completion expected January 2027
- MARITIME-CV: cardiovascular outcomes in atherosclerotic cardiovascular disease19, enrollment complete, primary completion expected June 2028
- Other Phase 3 studies1: heart failure, obstructive sleep apnea, and a type 2 diabetes trial against semaglutide
After Phase 3, a sponsor files a marketing application, and the FDA reviews it20 before deciding on approval. Amgen has announced no approval date. Until MARITIME reports, MariTide's safety record comes from earlier trials.
MariTide side effects seen in trials
Digestive effects were the most common side effects in Phase 215, and nausea and vomiting led in Phase 12. Most were mild to moderate, came mainly with early doses15, and grew less frequent with gradual dose escalation5. Phase 3 trials are collecting longer-term data on MariTide side effects and safety.
The bottom line on MariTide today
MariTide is an investigational once-monthly injection that blocks the GIP receptor and activates the GLP-1 receptor. Phase 2 showed weight loss vs placebo, Phase 3 MARITIME trials are underway, and the FDA has not approved MariTide.
Where can I learn about peptides?
MariTide appears under three names, and its Phase 3 trials are still running, so dependable updates can be hard to find. The team behind Superpower’s peptide library, made up of health journalists and licensed clinicians, writes and fact-checks every article, anchoring each claim in the research behind it.
Learn how designs like MariTide's join an antibody to peptides in Superpower's guides to the science behind peptides.
Important safety information
Maritide is an investigational drug currently under clinical development by Amgen. It has not been approved by the FDA, or any other regulatory authority, for any medical use. Because Maritide is not FDA-approved, does not appear on the FDA's 503A bulk drug substances list, and is not a component of any approved drug, it is not lawfully available through compounding pharmacies in the United States. Maritide is not prescribed, compounded, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.
Maritide is not available by prescription, is not available from compounding pharmacies, and is not sold or offered by Superpower. Any online product claiming to be maritide, AMG 133, or maridebart cafraglutide has not been approved or evaluated by the FDA.
Warnings: Several FDA-approved GLP-1 receptor agonists carry a boxed warning in their labeling regarding thyroid C-cell tumors observed in rodent studies. Maritide contains a GLP-1 agonist component but has no FDA-approved labeling. The clinical relevance in humans is not established but is monitored in clinical trials. GLP-1 receptor agonist compounds are associated with gastrointestinal adverse events including nausea, vomiting, and constipation, which may be severe in some individuals. These compounds are not recommended in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.
Maritide should not be used by anyone outside the active MARITIME clinical trial program; there is no approved indication and no contraindication table because there is no approved use. Populations of particular theoretical concern based on compound mechanism and trial exclusion criteria include: personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2; active malignancy with potential receptor expression; severe or uncontrolled gastroparesis; history of serious hypersensitivity to biologic therapeutics; pregnancy or breastfeeding; severe renal or hepatic impairment.
Common adverse events reported in trials: nausea and vomiting in Phase 1, and gastrointestinal effects in Phase 2, consistent with GLP-1 receptor agonist pharmacology. Long-term safety data in large populations are not yet available.
Weight regain: weight regain after discontinuation of GLP-1-class pharmacotherapy has been documented in published extension studies for approved compounds in this class. Maritide's post-dose weight maintenance signal from Phase 1 has not been confirmed in Phase 3 populations.
Full information for the investigational compound is available through the MARITIME clinical trial consent process at ClinicalTrials.gov21.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to maritide. Maritide is an investigational compound that is not FDA-approved; access is limited to clinical trial enrollment. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.